The decisions in the last 6 years were advised by the dough we had in the bank. So instead of doing just one phase 3 trial for ABSSI and exhausting all our resources , we went for multiple trials:
Phase 2a for Kevetrin
Phase 1 & 2 for OM
Phase 2 for Pruirisol
(I am leaving out the Oralogik trial)
I personally think that was a good move based on the funding constraints, but many on this board think otherwise.
But this time it is different. We have an health emergency with 170K+ dead...and counting, lackadaisical therapies in Remdesivir and others, with the efficacies of vaccines in trials still up in the air.
So if our first Covid trial succeeds (considering the excellent SI numbers we received today, I am confident we will) this stock will easily hit double digits. I would like to say triple considering that it would also be effective against other Coronoviruses, but why not be a little conservative. At this point this will be out of our hands because DoHHS will steamroll it to phase 3.
If the trial does not succeed, however, I fail to see how the stock will be priced higher than zero, because we would have exhausted all our resources by then. This will lead to a firesale of OM and other indications and at that point the company will cease to exist. There would also be no one on this board in a year's time.
But I would take the happy path because probabilistically our odds from today's numbers look very good. Payday is just a quarter away. The stock gyrations till that point are meaningless.
